Dow Down1.29% Nasdaq Down3.25%

Fidelity Select Biotechnology Portfolio (FBIOX)

162.97 Down 6.44(3.80%) Feb 5

Profile as of Jan 30, 2016Get Profile for:
Fidelity Select Biotechnology Portfolio
Fidelity Select Portfolios82 Devonshire StreetBoston MA 02109
Phone: 800-544-8544
Fund Overview 
Fund Family:Fidelity Investments
Net Assets:10.57B
Year-to-Date Return:-27.48%
Morningstar Rating:3 stars
Fund Inception Date:Dec 16, 1985
Morningstar Style Box 
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Rajiv Kaul
Lead Manager since Oct 12, 2005
Kaul is a portfolio manager with Fidelity Investments. Since joining Fidelity Investments in 1996, he has worked as a research analyst and portfolio manager. Kaul also manages another Fidelity fund. He is the recipient of the Kann Rasmusson Environment Award, the Dean's Summer Research Award and a Ford Undergraduate Fellowship.
Investment Information 
Min Initial Investment:2,500
Min Initial Investment, IRA:2,500
Min Initial Investment, AIP:N/A
Min Subsequent Investment:N/A
Min Subsequent Investment, IRA:N/A
Min Subsequent Investment, AIP:N/A
FBIOX can be purchased from 90 brokerages.

Fund Summary 
The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.

Fund Operations 
Last Dividend : 0.00
Last Cap Gain (Dec 3, 2015) : 0.00
Annual Holdings Turnover (Feb 3, 2016) : 61.00%
Average for Category:39.89%
Fees & Expenses 
ExpenseFBIOXCategory Avg
Annual Report Expense Ratio (net):0.74%1.36%
Prospectus Net Expense Ratio:0.74%N/A
Prospectus Gross Expense Ratio:0.74%N/A
Max 12b1 Fee:N/AN/A
Max Front End Sales Load:N/A5.28%
Max Deferred Sales Load: N/A2.38%
3 Yr Expense Projection*:237574
5 Yr Expense Projection*:411878
10 Yr Expense Projection*:9181,725
* Per $10,000 invested